Twist Bioscience inks deal with German Big Pharma worth up to $710M
Synthetic DNA maker Twist Bioscience Corporation has signed a research collaboration with Germany's Boehringer Ingelheim International that will turn the South San Francisco's biotech's library of propriety antibodies toward disease targets chosen by the Big Pharma company.
Twist will use what it terms its "Library of Libraries," a collection of synthetic DNA variant libraries used for rapid antibody discovery to help Boehringer find potential drug targets. Then Twist and Boehringer will collaborate…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Kevin Truong Source Type: news
More News: Biotechnology | Databases & Libraries | Germany Health | Health Management | Pharmaceuticals